- Oral presentation
- Open Access
Pharmacologic immunomodulation via adenosine 2a receptor stimulation improves LV remodeling and systolic strain in regions adjacent to the infarct as assessed by cardiac MRI
Journal of Cardiovascular Magnetic Resonance volume 18, Article number: O73 (2016)
Agonists of the Adenosine 2a Receptor (A2aR) are used clinically for perfusion imaging, but they are also potent immunomodulators that reduce infarct size in animal models when administered at reperfusion. The long term effects of sustained A2aR agonist administration initiated after myocardial infarction (MI) are largely unexplored. We hypothesized that sustained administration of an A2aR agonist would inhibit post-infarct left ventricular (LV) remodeling and improve contractile strain in the LV.
C57BL/6 mice were treated either with vehicle or a highly selective A2aR agonist (ATL313). All mice received 1h coronary occlusion and 28 days of reperfusion. ATL313 was administered for 28 days by subcutaneous micro-osmotic pumps implanted after MI. All mice underwent 7T CMR imaging at baseline and 2, 7, 14 & 28 days post-MI. CMR included short-axis black-blood cines covering the entire heart, with mid-ventricular cine DENSE (Displacement Encoding with Stimulated Echoes) for circumferential strain (Ecc). Late Gd-enhanced (LGE) inversion recovery imaging was performed on Days 2&7 and molecular imaging with a collagen-targeted Gd contrast agent (EP3533) was performed on Days 14&28. Mice with Day 2 LGE infarct sizes < 22% or >42% of LV mass were excluded from analysis.
Examples of LGE and DENSE strain mapping are shown in Panels A&B. Day 2 infarct size was similar between groups (ATL313 (n = 9): 35 ± 2 vs Vehicle (n = 8): 34 ± 2, mean ± SEM, p = NS). In Panel C, ATL313 significantly improved LV end-systolic volume as early as 2 days post-MI (mean ± SEM, *p < 0.05 vs Vehicle). In panel D, ATL313 improved Day 2 Ecc in adjacent zones vs. Vehicle (-10 ± 2 vs -6 ± 2%, *p < 0.05). In Panel E, ATL313 reduced LV mass at Day 28 vs Vehicle (121 ± 7 vs 143 ± 7 mg, *p < 0.05).
Pharmacologic immunomodulation with an A2aR agonist inhibits LV remodeling, improves contractile strain in infarct-adjacent regions at Day 2 post-MI and reduces LV mass at Day 28. Combined with previous work, these results suggest that A2aR stimulation may prove beneficial in both acute and sub-acute MI.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Cheng, YJ., Chemaly, E.R., Tian, Y. et al. Pharmacologic immunomodulation via adenosine 2a receptor stimulation improves LV remodeling and systolic strain in regions adjacent to the infarct as assessed by cardiac MRI. J Cardiovasc Magn Reson 18 (Suppl 1), O73 (2016). https://doi.org/10.1186/1532-429X-18-S1-O73
- Infarct Size
- Left Ventricular Remodel
- Inversion Recovery Imaging
- A2aR Agonist
- Reduce Left Ventricular Mass